Apogee Therapeutics, Inc. 8-K

What Happened

• Apogee Therapeutics, Inc. filed an 8-K (June 12, 2026) reporting the results of its 2026 Annual Meeting of Stockholders. As of the record date (April 15, 2026) there were 61,853,254 shares of voting common stock entitled to vote.
• Class III director nominees were elected to serve until the 2029 Annual Meeting: Mark C. McKenna (53,689,547 votes for; 1,515,704 withheld; 1,795,532 broker non‑votes), Jennifer Fox (52,895,552 for; 2,309,699 withheld; 1,795,532 broker non‑votes), and William (BJ) Jones, Jr. (44,964,804 for; 10,240,447 withheld; 1,795,532 broker non‑votes).
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 was ratified (56,960,778 for; 1,361 against; 38,644 abstentions).
• The company’s named executive officer compensation was approved on a non‑binding, advisory basis (54,324,725 for; 633,959 against; 246,567 abstentions; 1,795,532 broker non‑votes).

Key Details

• Record date shares: 61,853,254 shares entitled to vote (April 15, 2026).
• Director vote totals: McKenna 53,689,547 for; Fox 52,895,552 for; Jones 44,964,804 for (with larger withheld votes for Jones: 10,240,447).
• Auditor ratification: Ernst & Young LLP ratified with 56,960,778 votes in favor.
• Say-on-Pay: Advisory approval with 54,324,725 votes in favor.

Why It Matters

• These results finalize the board makeup for the next term (directors serve until the 2029 Annual Meeting) and confirm Ernst & Young as Apogee’s auditor for 2026—both governance items investors monitor for oversight and continuity.
• The advisory approval of executive compensation was passed (non‑binding), which means the board retains discretion but has shareholder support as reflected in the vote totals.
• Notable withheld votes (particularly for William Jones, Jr.) and broker non‑votes are factual indicators of shareholder voting patterns that investors may watch for context on investor sentiment and future governance discussions.